MonoSol Rx expands nanoparticle pact with Midatech; EyeGate launches pivotal trial

>  Drug delivery tech outfit MonoSol Rx expanded its pact with Midatech Group in the UK to develop nanoparticle-based proteins and peptides for therapeutic delivery using pharmaceutical films. Release

> MonoSol also announced that it has named Eric Dadey senior vice president, pharmaceutical development. Release

> Archimedes Pharma received a positive opinion from the Committee for Human Medicinal Products of the European Medicines Agency recommending PecFent, a fentanyl nasal spray, for the treatment of breakthrough cancer pain. Release

> EyeGate Pharma, which is developing a non-invasive ocular drug delivery platform and ocular drugs, has begun enrolling patients in the pivotal Phase III study of its lead product, EGP-437, for the treatment of Dry Eye Syndrome. Release

> Innomech has struck a deal to develop an end-of-line testing system for a new drug delivery pen. Story

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.